The average one-year price target for Biofrontera Inc. is $ The forecasts range from a low of $ to a high of $ A stock's price target is the. BFRI News · Earnings call: Biofrontera reports strong Q2 growth, reduces debt · Biofrontera target cut to $16 from $25 on second-quarter results · Biofrontera. Biofrontera (BFRI) has a Smart Score of N/A based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund. On Wednesday 08/14/ the closing price of the Biofrontera Inc Registered Shs share was $ on BTT. Compared to the opening price on Wednesday 08/14/ on. Biofrontera (bitcoinstorm.site): The Q1 financial report achieved revenue of US$ million, with a previous value of US$ million and an expected value of US.
Recent News & Updates · BFRI Stock Earnings: Biofrontera Misses EPS, Misses Revenue for Q1 (Investorplace) · Biofrontera. Track Biofrontera Inc (BFRI) Stock Price, Quote, latest community messages, chart, news and other stock related information. Biofrontera Second Quarter Earnings: EPS Beats Expectations, Revenues Lag. Biofrontera (NASDAQ:BFRI) Second Quarter Results Key Financial Results. Biofrontera Inc. (NASDAQ:BFRI - Get Free Report) was the target of a significant decline in short interest during the month of March. As of March 15th, there. Biofrontera Inc. Announces Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals. First Prev Last Next. View the latest Biofrontera Inc. (BFRI) stock price, news, historical charts, analyst ratings and financial information from WSJ. BFRI | Complete Biofrontera Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Biofrontera's principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic. Biofrontera Inc. ; Open. ; High. ; 52wk High. ; Volume. k ; Beta. Biofrontera Inc. (NASDAQ:BFRI) reported financial results for Q2 , showing significant growth. Total revenues increased 34% to $ million compared to Q2. Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of.
BFRI stock results show that Biofrontera missed analyst estimates for earnings per share and missed on revenue for the first quarter of 3 Mind-Blowing. · PTA-News: Biofrontera AG: Commercial launch of Ameluz® in Finland · PTA-News: Biofrontera AG: Biofrontera establishes UK subsidiary to strengthen its sales. Biofrontera, Inc. (BFRI) reports record revenues of $M for , a 19% increase from Operating expenses were $M, with a 4% revenue increase in Q4. Biofrontera News More News · Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp · Analysts Offer Insights on. Biofrontera Inc. is currently listed on NASDAQ under BFRI. One share of BFRI stock can currently be purchased for approximately $ Is. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in. BFRI Stock Overview · Earnings are forecast to grow % per year · Trading at good value compared to peers and industry · Does not have a meaningful market. Biofrontera (BFRI) reported Q1 earnings per share (EPS) of -$, missing estimates of -$ by %. In the same quarter last year, Biofrontera's. Monday, June 24, · Biofrontera shares are trading higher after t Benzinga Newsdesk - Jun 24, , AM · Biofrontera Launches A New, FDA-Approved Red.
Stay up-to-date on Biofrontera Inc. Common Stock (BFRI) news with the latest updates, breaking headlines, news articles, and more from around the web at. Get Biofrontera Inc (BFRI:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Given the current short-term trend, the stock is expected to rise % during the next 3 months and, with a 90% probability hold a price between $ and. Based on 2 Wall Street analysts offering 12 month price targets for Biofrontera in the last 3 months. The average price target is $ with a high forecast of. News ; Biofrontera Second Quarter Earnings: EPS Beats Expectations, Revenues Lag. Yahoo Finance ; Biofrontera Analyst Ratings. BenzingaAug 16 ET.
Biofrontera Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BFRI. The last closing price for Biofrontera was $ Over the.